Marché mondial de la prophylaxie antirotavirus – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et taille du marché

Ces dernières années, le marché de la prophylaxie antirotavirus devrait connaître une croissance rapide au cours de la période de prévision. Le rotavirus est un virus qui infecte facilement les enfants et les nouveau-nés. Une diarrhée aqueuse sévère , de la fièvre, des vomissements et des douleurs abdominales sont tous des symptômes de l'infection. Dans les cinq ans suivant la naissance, pratiquement tous les enfants aux États-Unis ont au moins une infection à rotavirus ; plus de 400 000 enfants sont envoyés chez le médecin pour y être soignés ; et environ 50 à 60 enfants meurent chaque année.

Français Data Bridge Market Research analyse que le marché de la prophylaxie contre le rotavirus était évalué à 7,415 milliards USD en 2021 et devrait atteindre 15,66 milliards USD d'ici 2029, enregistrant un TCAC de 9,80 % au cours de la période de prévision de 2022 à 2029. Le rapport de marché organisé par l'équipe Data Bridge Market Research comprend une analyse approfondie des experts, une épidémiologie des patients, une analyse du pipeline, une analyse des prix et un cadre réglementaire.

Définition du marché

Le rotavirus est un virus évitable par la vaccination de la famille des réoviridés qui provoque des diarrhées et une déshydratation. Il se transmet par l'intermédiaire de personnes infectées ou de surfaces contaminées. La fièvre et les vomissements sont les premiers signes et symptômes que ressentent les patients atteints d'une infection à rotavirus. Même si les infections à rotavirus sont désagréables, vous pouvez généralement les traiter à domicile en buvant beaucoup d'eau pour éviter la déshydratation. Une déshydratation sévère peut nécessiter l'injection de liquides par voie intraveineuse à l'hôpital.

Portée du rapport et segmentation du marché

Rotavirus Prophylaxis Market Dynamics

Drivers

• Increasing prevalence of rotavirus infection

The rising prevalence of rotavirus infection is anticipated to propel the rotavirus prophylaxis market's growth rate. Because of their poor hygiene habits, rotavirus sickness is highly contagious and spreads quickly among children. In hospitals as well as day-care centres, rotavirus infection is a widespread healthcare issue. Another factor driving the rotavirus vaccine market is support from UNICEF and GAVI (a vaccine alliance of multiple countries under which 45 countries have been approved for rotavirus vaccine support) for large-scale vaccination, supply availability, and access to affordable prices.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of rotavirus prophylaxis market is the rising healthcare expenditure which helps in improving its infrastructure.  

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the rotavirus prophylaxis market. Additionally, high disposable income and continuously changing lifestyle pf people will result in the expansion of rotavirus prophylaxis market. Along with this, favourable government policies are estimated to enhance the market's growth rate.

Opportunities

• Increase in the number of research and development activities       

The market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the rotavirus prophylaxis market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising demand for vaccine and an increase in the number of emerging markets will further provide beneficial opportunities for the rotavirus prophylaxis market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the rotavirus prophylaxis market. Additionally, a decline in clinical visits due to COVID-19 outbreak and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This rotavirus prophylaxis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the rotavirus prophylaxis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Rotavirus prophylaxis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Rotavirus Prophylaxis Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems around the world were severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations had a negative impact on the market of rotavirus prophylaxis.

Global Rotavirus Prophylaxis market Scope

The rotavirus prophylaxis market is segmented on the basis of treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Rotarix
• Rotavac
• Rotavin-M1
• Lanzhou Lamb
• Oral Rehydration Fluid
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Rotavirus Prophylaxis Market Regional Analysis/Insights

The Rotavirus prophylaxis market is analysed and market size insights and trends are provided by country, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Rotavirus prophylaxis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the rotavirus prophylaxis market because of the growing prevalence of rotavirus and surging demand for disease-specific treatment. Additionally, presence of well-established healthcare infrastructure and growing awareness among patients will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period of 2022 to 2029 due to the increasing number of generic manufacturers and rising healthcare expenditure in this region. Furthermore, growing level of disposable income will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Rotavirus Prophylaxis Market Share Analysis

The Rotavirus prophylaxis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to rotavirus prophylaxis market.

Some of the major players operating in the rotavirus prophylaxis market are:

• Sanofi (France)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• Novartis SA (Suisse)
• Merck & Co., Inc. (États-Unis)
• Bharat Serums and Vaccines Limited (Inde)
• Bharat Biotech (Inde)
• Institut de recherche médicale QIMR Berghofer (Australie)
• Serum Institute of India Pvt. Ltd. (Inde)
• Biological E Limited (Inde)
• Bio Farma (Indonésie)
• Astellas Pharma Inc. (Japon)
• CSL Limited (Australie)
• Johnson & Johnson Private Limited (États-Unis)
• DAIICHI SANKYO COMPANY, LIMITED (Japon)
• Mitsubishi Tanabe Pharma Corporation (Japon)
• AstraZeneca (Royaume-Uni)

SKU-53516